Lv3
290 积分 2023-02-18 加入
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
12天前
已关闭
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
18天前
已完结
New Estimates on the Cost of a Delay Day in Drug Development
19天前
已完结
Optimized indocyanine green nanopreparations for biomedical applications
1个月前
已完结
Lung Tumors Marked Percutaneously with Indocyanine Green Dye–Soaked Embolization Coils: A Visual Beacon for Accurate Intraoperative Localization during Lung-Sparing Surgery
1个月前
已完结
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
1个月前
已完结
274MO Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the mainland China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the phase III HIMALAYA study
1个月前
已关闭
Relationship between stroke recurrence, infarct pattern, and vascular distribution in patients with symptomatic intracranial stenosis
1个月前
已完结
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
2个月前
已完结
274MO Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the mainland China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the phase III HIMALAYA study
4个月前
已关闭
皖公网安备34019202002308
